Fong Y, Huang Y, Huang Y, Woo W, McGarry A, ??ez G, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb W, Lu Y, Yu C, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Rodriguez CA, Tapia M, Turley CB, Zorrilla CD, Cohen SH, Kline SE, Barranco E, Corey L, Neuzil KM, Follmann D, Ake JA, Gay CL, Kotloff KL, Jones T, Koup RA, Donis RO, Gilbert PB. Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine. Clin Infect Dis. 2026 Apr 30; 82(4):e863-e874.

Heng F, Magaret CA, Rouphael NG, Branche AR, Fong Y, Carpp LN, Yu C, Chen S, Zhang B, Diemert DJ, Falsey AR, Graciaa DS, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, B?cker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Simon V, van Bakel H, Roberts PC, Gilbert PB. The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.

Cinkovich SC, Althouse BM, Hitchings MDT, Bonnaire-Fils P, Diop OM, Faye O, Faye EHA, Diallo D, Sadio BD, Sow A, Faye O, Diallo M, Benefit B, Watts DM, Sall AA, Weaver SC, Hanley KA, Cummings DAT. Seroprevalence of dengue virus antibodies among multiple species of non-human primates in Senegal suggests that sylvatic dengue virus is maintained in non-primate reservoirs in this region. PLoS Negl Trop Dis. 2026 Jan; 20(1):e0013946.

Falc?o de Oliveira E, Carvalho AT, Venancio FA, Quili?o ME, Gabeira SCO, Leite SHDS, Sal? MDS, Lima SMB, Alves NDS, Moura LDC, Schwarcz WD, Azevedo AS, Demarchi LHF, Zardin MCSU, Lichs GGC, Taira DL, Nascimento AID, Fernandes WS, Alves NO, Casaril Arrua AE, Medeiros MJ, Cunha RVD, Vasconcelos Z, Santos-Pinto CDB, Nielsen-Saines K. Zika virus infection in early pregnancy increases the likelihood of persistent neutralizing antibodies. PLoS Negl Trop Dis. 2026 Jan; 20(1):e0013906.

Stromberg ZR, Silva EE, Johnston SC, Johnson DM, Hall D, Adjei EF, Altin JA, Abisoye-Ogunniyan A, Gollott T, He W, Jones IKA, Kwilas S, Lund SJ, Mead HL, Nelson GA, Ouyang L, Peters SKG, Schwedler JL, Trecazzi CZ, Turner MW, Ye C, Bradfute SB, Fischer NO, Hooper JW, Ladner JT, Rasley A, Negrete OA. An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models. Front Immunol. 2025; 16:1682418.

Cardona-Ospina JA, Roy V, Marcano-Jim?nez DE, Bos S, Duarte E, Zambrana JV, Bal A, An BK, Dias AG, Zhiteneva J, Huffaker J, Montenegro C, Kuan G, Ramos-Benitez MJ, Balmaseda A, Alter G, Harris E. IgA-driven neutrophil activation underlies severe dengue disease after primary Zika virus infection in humans. Nat Immunol. 2026 Jan; 27(1):126-134.

Tuchynskaya K, Vorovitch M, Kruglov Y, Mostipanova G, Kholodilov I, Ivanova A, Kuchina V, Rogova A, Karganova G. Mono-WNV and combined WNV/TBEV inactivated vaccine efficacy against a wide range of WNV and TBEV strains. Front Immunol. 2025; 16:1715371.

Cruz A, Ramos-Cartagena JM, Panicker G, P?rez CM, Su?rez E, Romaguera J, Unger ER, Rivera T, Ortiz AP. Seroprevalence of nine human papillomavirus types included in the nonavalent vaccine in unvaccinated women living in Puerto Rico: A population-based study. Int J Infect Dis. 2026 Feb; 163:108195.

Jeong E, Oh SY, Son SU, Lee S, Kim R, Lim J, Kim S, Kang T, Jung J, Seong SY, Jang IY, Kim JH, Jang E, Jeong HH, Lim EK, Haam S. Nanobody engineering for enhanced-sensitivity rapid COVID-19 tests. Nanoscale. 2025 Oct 16; 17(40):23329-23342.

Dokal K, Channon-Wells S, Davis C, Estrada-Rivadeneyra D, Huse KK, Lias A, Hamilton S, Guy RL, Lamagni T, Nichols S, Taylor A, Agyeman PKA, Anpananthar A, Basmaci R, Carrol ED, Carter MJ, De T, de Jonge MI, Emonts M, Elorrieta LE, Fidler K, Kolnik M, Kuijpers TW, Martinon-Torres F, Moll H, Mommert-Tripon M, Neshat S, Nyirenda-Nyang'wa M, O'Riordan S, Owens DR, Pathan N, Paulus S, Peters MJ, Pokorn M, Pollard AJ, Rivero-Calle I, Rojo P, Romani L, Rughani P, Schlapbach LJ, Schweintzger NA, Shen CF, Sulik A, Tsolia M, Usuf E, van der Flier M, Vermont C, von Both U, Wellman P, Wright VJ, Yeung S, Zavadska D, Cunnington AJ, Fink C, Herberg J, Kaforou M, Sriskandan S, Levin M, Parks T. Immunity to Streptococcus pyogenes and Common Respiratory Viruses at Age 0 to 4 Years After COVID-19 Restrictions. JAMA Netw Open. 2025 Oct 01; 8(10):e2537808.